BIOPSYPEN

OPTICAL BIOPSY PEN: A COMPACT AND LOW-COST DIAGNOSTIC TOOL FOR DERMATOLOGY BASED ON HIGH-PERFORMING INTEGRATED OCT

Coordinatore	MEDLUMICS    more  Organization address address: RONDA DE PONIENTE 16-1E city: TRES CANTOS postcode: 28760 contact info Titolo: Dr. Nome: Jose Luis Cognome: Rubio Email: send email Telefono: 34918033925 Fax: 34918049321
Nazionalità Coordinatore	Spain [ES]
Totale costo	4˙666˙979 €
EC contributo	3˙600˙000 €
Programma	FP7-ICT Specific Programme "Cooperation": Information and communication technologies
Code Call	FP7-ICT-2013-10
Funding Scheme	CP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2016-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	MEDLUMICS  Organization address address: RONDA DE PONIENTE 16-1E city: TRES CANTOS postcode: 28760 contact info Titolo: Dr. Nome: Jose Luis Cognome: Rubio Email: send email Telefono: 34918033925 Fax: 34918049321	ES (TRES CANTOS)	coordinator	0.00
2	EXALOS AG  Organization address address: WAGISTRASSE city: SCHLIEREN postcode: 8952 contact info Titolo: Dr. Nome: Christian Cognome: Velez Email: send email Telefono: +41 434446092	CH (SCHLIEREN)	participant	0.00
3	MEDIZINISCHE UNIVERSITAET WIEN  Organization address address: SPITALGASSE city: WIEN postcode: 1090 contact info Titolo: Dr. Nome: Wolfgang Cognome: Drexler Email: send email Telefono: +0043 1404001986	AT (WIEN)	participant	0.00
4	Optocap Ltd  Organization address address: Bain Square city: Livingston postcode: EH54 7DQ contact info Titolo: Mr. Nome: Stephen Cognome: Duffy Email: send email Telefono: +44 1506403550	UK (Livingston)	participant	0.00
5	TECHNISCHE UNIVERSITEIT DELFT  Organization address address: Stevinweg city: DELFT postcode: 2628 CN contact info Titolo: Prof. Nome: Lina Cognome: Sarro Email: send email Telefono: +31 152787708	NL (DELFT)	participant	0.00
6	TEKNOLOGIAN TUTKIMUSKESKUS VTT  Organization address address: TEKNIIKANTIE city: ESPOO postcode: 02044 VTT contact info Titolo: Dr. Nome: Timo Cognome: Aalto Email: send email Telefono: +358 207226694	FI (ESPOO)	participant	0.00
7	UNIVERSIDAD POLITECNICA DE MADRID  Organization address address: CALLE RAMIRO DE MAEZTU city: MADRID postcode: 28040 contact info Titolo: Prof. Nome: Roberto Cognome: PRIETO Email: send email Telefono: +34 913366048 Fax: +34 913365974	ES (MADRID)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

Optical coherence tomography (OCT) is an emerging optical diagnosis that enables in vivo tomographic visualization for non-invasive optical biopsy. OCT has proven its value primarily in ophthalmology, but recently also in dermatology. However, wide adoption has not taken place due to size and cost limitations as well as non-existence of handheld devices.nHence BIOPSYPEN will develop a new OCT generation with step-changes in size and cost beyond state-of-the-art to radically transform OCT instrumentation for handheld point-of-care diagnosis. In contrast to conventional approaches, BIOPSYPEN's OCT is based on integrated optics, more precisely on hybrid integration of silicon photonics with III-V sources, enabling a significantly smaller, low-cost, compact and maintenance free alternative.nBIOPSYPEN will target complementary research to develop an unprecedented compact (pencil-like), reliable, low-cost, battery-operated, wireless handheld OCT device in combination with an embedded system based external console to receive two-and three-dimensional tomograms for instantaneous post processing and visualization as well as immediate diagnosis.nBIOPSYPEN will contribute to a significantly wider adoption of OCT in real clinical point of care settings. Early diagnosis of skin cancer and inflammatory skin diseases are envisaged. Skin cancer will be used as a surrogate for other epithelial cancers, e.g. oral, gynaecologic or gastrointestinal cancer. Partnerships with leading innovative clinical users will enable preclinical evaluation.nThrough the use of integrated optics in combination with complementary cutting-edge technologies, BIOPSYPEN will dramatically reduce cost and size (both at least by one order of magnitude) of currently available OCT commercial systems. It will also eliminate instrumentation maintenance requirements and will reduce training and healthcare costs, paving the way to revolutionize diagnosis for general medicine and primary care.